GI / Hepatology
Primary Biliary Cholangitis / Primary Sclerosing Cholangitis
Differentiate PBC (AMA+, female, intrahepatic, UDCA-responsive) from PSC (M>F, IBD association, MRCP, no proven medical therapy).
Source: EASL 2017 PBC; EASL 2022 PSC; BSG
Step 1 of ~3
question
Suspected Diagnosis
Differentiate based on demographics + serology + imaging.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Obeticholic Acid · FXR Agonist (Primary Biliary Cholangitis)
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Febuxostat · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Nicotine · Nicotine replacement therapy (NRT)
- Eliglustat · Glucosylceramide synthase inhibitor (substrate reduction therapy)
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
Decision support only. Always apply local guidelines and clinical judgement.